Indian drugmaker Biocon-backed Equillium, a California-based biotechnology company, plans to raise up to $86 million through an initial public offering (IPO), according to a filing with the U.S. Securities and Exchange Commission (SEC).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
